Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Congressional Report Finds FDA Ignored Agency Protocols in Approving Biogen’s Aduhelm Alzheimer’s Drug Biogen and FDA held numerous improperly documented meetings designed to drag Aduhelm through the approval process despite a lack of evidence showing the drug worked, the report found December 30, 2022 Irvin Jackson Add Your Comments Concerns have been raised about whether federal drug regulators failed to follow their own standard protocols when approving the controversial Alzheimer’s disease drug Aduhelm, after a new Congressional report suggests that the FDA had an unusually close relationship with Biogen, the manufacturer. Aduhelm became the first novel therapy approved for the treatment of Alzheimer’s since 2003, after it was granted approval through the FDA’s Accelerated Approval Program in June 2022. The drug is designed to reduce the presence of amyloid beta plaques in the brain, which are believed to be linked to the progression of the disease. However, the decision to approve the medication immediately raised questions, since it followed the unanimous recommendation against approval by a panel of independent advisors to the FDA, due to questions about Aduhelm’s effectiveness treating Alzheimer’s. Following an 18 month investigation that looked into why the drug was approved, a joint report was released this week by the U.S. House of Representative’s Committee on Oversight and Reform, and Committee on Energy and Commerce, titled “The High Price of Aduhlem’s Approval” (PDF), highlighting the overly cozy releationship between the FDA and Biogen. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The agency’s approval led to several members of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee resigning in protest, and several congressional committees are looking into the decision. The agency has since faced a number of serious questions, such as why the FDA approved the drug when its own experts said it should not, and whether there was an improper working relationship between the agency and the drug’s manufacturer, Biogen. Lawmakers Question FDA, Biogen Relationship and Aduhelm Approval House staffers reviewed more than 500,000 pages on documents and held multiple briefings with the FDA. “The Committees’ review of these materials reveals that FDA’s review and approval of Aduhelm consisted of atypical procedures and deviated from the agency’s own guidance,” the report determines. “These materials also reveal that Biogen had aggressive launch plans for Aduhelm – including in its label and pricing – despite concerns about efficacy, safety, and affordability.” The House report notes that the FDA’s accelerated approval of Aduhelm occurred despite the fact that Biogen had cancelled clinical trials for the Alzheimer’s drug in March 2019. Aduhelm is supposed to reduce amyloid beta plaque in the brain, but an independent report at the time found it was unlikely to be a benefit to Alzheimer’s patients and determined no further clinical trials should be conducted. However, just three months after the clinical trials were cancelled, FDA staff members and Biogen formed a “working group” which engaged in at least 115 meetings, calls and email discussions over the next year. At least 40 of those meetings were focused on dragging Aduhelm through the approval process despite evidence the drug just did not work. The House investigators found some of the meetings were not properly documented according to FDA protocols, raising suspicions. The report determined that the FDA’s interactions with Biogen were atypical, failing to follow the agency’s documentation protocol on many occasions, making it hard to determine what happened at those meetings. At least 40 working group meetings between FDA staff and Biogen, 66 phone calls and a substantial number of email exchanges were not properly documented, House staffers determined. House investigators also found that the FDA and Biogen inappropriately collaborated to create a joint briefing document for the FDA Advisory Committee. Even that was not enough to prevent the FDA’s advisors from resoundingly rejecting Aduhelm, which did not stop the FDA from approving it. “The Committees obtained evidence that FDA and Biogen staff worked closely for several months ahead of the November 6, 2020, PCNS Advisory Committee meeting to prepare the joint briefing document for the Committee’s review,” the investigators wrote. “Documents show that using a joint briefing document afforded Biogen advance insight into FDA’s responses and direct guidance from the agency in drafting the company’s own sections.” Despite the failed clinical trials, and despite the rejection by the FDA’s own panel of advisors, the agency granted Aduhelm accelerated approval anyway, and then when the drug came out, investigators found that Biogen planned to set an unusually high price of $56,000 per year for treatment. Then the company planned to spend $3.3 billion to market the drug, which is three times how much it cost to develop. “The findings in this report raise serious concerns about FDA’s lapses in protocol and Biogen’s disregard of efficacy and access in the approval process for Aduhelm,” the report concludes “The criticism surrounding Aduhelm’s approval pay have been avoided had FDA adhered to its own guidance and internal practices. FDA must take swift action to ensure that its process for reviewing future Alzheimer’s disease treatments do not lead to the same doubts about the integrity of FDA’s review.” Tags: Aduhelm, Alzheimer's Disease, Biogen, Congress More Lawsuit Stories Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis May 1, 2025 Nitrous Oxide Addiction Lawsuit Claims Manufacturer Concealed Galaxy Gas Side Effects May 1, 2025 Roundup Exposure May Increase Infertility, Endometriosis Risks: Study May 1, 2025 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (Posted: today) A Wisconsin woman has filed a Depo-Provera brain tumor lawsuit, alleging that she continued using the birth control injection for years after her diagnosis due to the manufacturers’ failure to provide adequate warnings about the potential risk of developing a meningioma. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)Depo-Provera Use for Endometriosis Caused Stroke-Like Symptoms, Golf Ball-Sized Brain Tumor: Lawsuit (04/15/2025)Depo-Provera Lawsuit Case Management Conferences Scheduled Throughout 2025 (04/08/2025) Sports Gambling Addiction Crisis Fueled By Sportsbook App Lobbying Efforts: Report (Posted: yesterday) Following the rapid expansion of legalized sports betting across the U.S., a new watchdog report reveals how the gambling industry lobbied against consumer protections to prevent sports betting addictions, while wagers reached $148 billion annually. MORE ABOUT: SPORTS BETTING ADDICTION LAWSUITDraftKings Class Action Lawsuit Alleges Enormous Revenue Generated by Misleading Gamblers (04/23/2025)DraftKings and FanDuel Lawsuit Alleges Sportsbooks Engage in Deceptive Practices To Exploit Gambling Addiction (04/09/2025)Gambling Addiction Lawsuit Filed Against Sports Betting Platform DraftKings (02/20/2025) Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (Posted: yesterday) A group of 11 lawsuits over complications associated with Bard PowerPort and other implantable port catheters will be prepared for a series of early bellwether trials in the federal MDL. MORE ABOUT: BARD POWERPORT LAWSUITBard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)Bard PowerPort Bellwether Trial Selections To Be Made in Late April 2025 (03/26/2025)Smiths Medical Port Catheter Recall Issued Over Manufacturing Error (03/20/2025)
Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis May 1, 2025
Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (Posted: today) A Wisconsin woman has filed a Depo-Provera brain tumor lawsuit, alleging that she continued using the birth control injection for years after her diagnosis due to the manufacturers’ failure to provide adequate warnings about the potential risk of developing a meningioma. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)Depo-Provera Use for Endometriosis Caused Stroke-Like Symptoms, Golf Ball-Sized Brain Tumor: Lawsuit (04/15/2025)Depo-Provera Lawsuit Case Management Conferences Scheduled Throughout 2025 (04/08/2025)
Sports Gambling Addiction Crisis Fueled By Sportsbook App Lobbying Efforts: Report (Posted: yesterday) Following the rapid expansion of legalized sports betting across the U.S., a new watchdog report reveals how the gambling industry lobbied against consumer protections to prevent sports betting addictions, while wagers reached $148 billion annually. MORE ABOUT: SPORTS BETTING ADDICTION LAWSUITDraftKings Class Action Lawsuit Alleges Enormous Revenue Generated by Misleading Gamblers (04/23/2025)DraftKings and FanDuel Lawsuit Alleges Sportsbooks Engage in Deceptive Practices To Exploit Gambling Addiction (04/09/2025)Gambling Addiction Lawsuit Filed Against Sports Betting Platform DraftKings (02/20/2025)
Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (Posted: yesterday) A group of 11 lawsuits over complications associated with Bard PowerPort and other implantable port catheters will be prepared for a series of early bellwether trials in the federal MDL. MORE ABOUT: BARD POWERPORT LAWSUITBard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)Bard PowerPort Bellwether Trial Selections To Be Made in Late April 2025 (03/26/2025)Smiths Medical Port Catheter Recall Issued Over Manufacturing Error (03/20/2025)